VIDEO: Exciting results from three studies testing CAR-T cell vs standard of care
Click Here to Manage Email Alerts
In this video, Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center discusses three randomized trials testing CD19-directed autologous chimeric antigen receptor T-cell therapies against chemotherapy and autologous transplant in the second line setting for lymphoma, which were presented at ASH.
The three studies included the ZUMA-7 phase 3 clinical trial, which tested the efficacy of axicabtagene ciloleucel vs. standard of care in patients with relapsed/refractory large B-cell lymphoma; the TRANSFORM trial, which tested lisocabtagene maraleucel vs. standard of care with salvage chemotherapy; and the Belinda study, which tested tisagenlecleucel against standard of care as second line therapy.
"Overall, I think it is exciting times for CAR T-cell therapy in large B-cell lymphoma," Locke said.
Collapse
Bishop MR, et al. Abstract LBA-6. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Elsawy M, et al. Abstract 430. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Kamdar M, et al. Abstract 91. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Click Here to Manage Email Alerts